Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Characterizing the impact of a novel therapeutic on the poultry gut microbiome

FY 2015-16

Summary
Salmonella infections represent a significant public health concern. Sources of infection include contaminated meat, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is an important means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic that could be provided to commercial growers to prevent and/or eliminate Salmonella in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy in cell culture. The next step requires testing efficacy in vivo in pre-harvest chicken flocks. Parallel studies are required to determine the impact of these therapeutics on the poultry microbiome. The intestinal microbiota in poultry is critical for maintenance of health and defense against pathogens. It is imperative to demonstrate that these antibodies, when administered at therapeutic levels, are capable of eliminating Salmonella while leaving other members of the normal poultry flora intact. This work capitalizes on the microbiome analysis expertise of the Mohn Laboratory, whose work will complement the expertise of the larger research team. This project proposes to: (1) use high-throughput DNA sequencing and bioinformatic analysis to characterize and compare the gut microbiome of healthy, Salmonella-infected and antibody-treated poultry, (2) determine any effects of antibody therapy on the microbiome, (3) compare the impact on the microbiome of antibody-delivered therapeutics versus traditional antibiotic-based therapies currently used to control Salmonella infection. Development of a Salmonella-selective therapeutic that has minimal effects on host physiology and normal flora, will benefit Canadians and worldwide populations by eliminating a source of antibiotics in the food chain while reducing human infection and illness, loss of life and costs of treatment.
Program
Engage Grants Program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
487402-2015
Name nom
Mohn, William
Department département
Microbiology and Immunology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
101
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal production and animal primary products
Area of application fr
Production animale et produits animaux primaires
Research subject code
4714
Research subject group en
Evolution and ecology
Research subject group fr
Évolution et écologie
Research subject en
Microbial ecology
Research subject fr
Écologie microbienne
Partie
1
Nb partie
1
Application title
Characterizing the impact of a novel therapeutic on the poultry gut microbiome
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern. Sources of infection include contaminated meat, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is an important means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic that could be provided to commercial growers to prevent and/or eliminate Salmonella in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and are being tested for their efficacy in cell culture. The next step requires testing efficacy in vivo in pre-harvest chicken flocks. Parallel studies are required to determine the impact of these therapeutics on the poultry microbiome. The intestinal microbiota in poultry is critical for maintenance of health and defense against pathogens. It is imperative to demonstrate that these antibodies, when administered at therapeutic levels, are capable of eliminating Salmonella while leaving other members of the normal poultry flora intact. This work capitalizes on the microbiome analysis expertise of the Mohn Laboratory, whose work will complement the expertise of the larger research team. This project proposes to: (1) use high-throughput DNA sequencing and bioinformatic analysis to characterize and compare the gut microbiome of healthy, Salmonella-infected and antibody-treated poultry, (2) determine any effects of antibody therapy on the microbiome, (3) compare the impact on the microbiome of antibody-delivered therapeutics versus traditional antibiotic-based therapies currently used to control Salmonella infection. Development of a Salmonella-selective therapeutic that has minimal effects on host physiology and normal flora, will benefit Canadians and worldwide populations by eliminating a source of antibiotics in the food chain while reducing human infection and illness, loss of life and costs of treatment.